Calithera Biosciences Inc. (NASDAQ:CALA) shot up 6% during mid-day trading on Monday . The company traded as high as $3.34 and last traded at $3.34, with a volume of 94,076 shares trading hands. The stock had previously closed at $3.15.

A number of brokerages recently issued reports on CALA. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $10.38.

The firm has a 50-day moving average of $3.39 and a 200-day moving average of $4.84. The company’s market cap is $62.17 million.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. On average, equities research analysts forecast that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.